May 18-19, 2016; Amsterdam; the Netherlands 6 TH DUTCH BREAST PATHOLOGY COURSE. Finding the balance between overtreatment and undertreatment

Size: px

Start display at page:

Download "May 18-19, 2016; Amsterdam; the Netherlands 6 TH DUTCH BREAST PATHOLOGY COURSE. Finding the balance between overtreatment and undertreatment"

Ashlie Rice
5 years ago
Views:

1 May 18-19, 2016; Amsterdam; the Netherlands 6 TH DUTCH BREAST PATHOLOGY COURSE Finding the balance between overtreatment and undertreatment

2 Dear colleague, On the road to patient-tailored medicine, breast pathology is facing a huge challenge due to new morphological, molecular, and therapeutic insights. Therefore, we organize an international multidisciplinary breast pathology course, focusing on the central and decisive role of the modern pathologist in finding the balance between overtreatment and undertreatment of breast disease. Issues to be discussed include how we can distinguish harmless from hazardous intraductal lesions, how we manage sentinel lymph node involvement in breast cancer, and how we select more precisely breast cancer patients that will benefit from systemic treatment. We cordially invite pathologists and pathology residents in the last year of their training for the 6th Dutch Breast Pathology Course on May 18-19, This interactive and multidisciplinary course consists of workshops, case studies, lectures, and debates about relevant issues for the up-to-date breast pathologist. Aiming at a dynamic and instructive meeting, we are looking forward to your participation. In total, we can host 50 participants. Kind regards, also on behalf of Emilie Groen, Koen van de Vijver, Hugo Horlings, and Mathilde Almekinders, Jelle Wesseling, MD. PhD. Pathologist, Divisions of Diagnostic Oncology & Molecular Pathology, Netherlands

3 PROGRAM Wednesday May 18, Registration & Coffee Introduction Jelle Wesseling, pathologist The role of pathology in minimizing harm by breast surgery Hester Oldenburg, surgical oncologist Conquering overdiagnosis by cytopathology Claudette Loo, radiologist & Koen van de Vijver, pathologist Coffee break Workshop: do neuroendocrine features of breast lesions really matter? Malcolm Hayes, pathologist, University of British Colombia, Vancouver The multidisciplinary clinical breast care team meeting at the NKI-AVL Breast team The Netherlands Cancer Institute Lunch Distinguishing harmless from hazardous breast lesions Jelle Wesseling, pathologist Diagnosis, treatment and prognosis of adenomyoepithelial lesions Malcolm Hayes, pathologist University of British Colombia, Vancouver Tea Break The role of pathology in saving the axilla Mila Donker, radiation oncologist in training Improving response prediction by pathology in neoadjuvant treatment Esther Lips, molecular biologist Debate: Standard breast pathology: too little and too much Pro too little and too much: Emiel Rutgers, breast surgeon Pro standard: TBA Drinks and dinner Location to be announced

4 PROGRAM Thursday May 19, Workshop: diagnosis and prognosis of papillary lesions Malcolm Hayes, pathologist University of British Colombia, Vancouver Coffee Break The role of pathology in targeting neoadjuvant treatment Gabe Sonke, medical oncologist Workshop breast lesions illustrating the overdiagnosis dilemma All participants are invited to submit a case illustrating the theme of this course. Maximal 15 cases will be selected for a plenary discussion. See instructions above. This invitation will be sent after your registration has been confirmed Lunch Molecular pathology in precise breast cancer management Hugo Horlings, pathologist Striving for the optimum in breast conserving therapy Harry Bartelink, radiation oncologist The role of the pathologist in deescalating systemic treatment Carolien Schröder, medical oncologist, University Medical Center Groningen, NL Tea Break Debate: Histopathology vs. molecular tests driving systemic treatment decisions Pro histopathology: Carolien Schröder, medical oncologist University Medical Center Groningen, NL Pro molecular tests: Sabine Linn, medical oncologist Evaluation and closing remarks

5 FACULTY Name Almekinders, Mathilde Bartelink, Harry Donker, Mila Groen, Emilie Hayes, Malcolm Horlings, Hugo Linn, Sabine Lips, Esther Loo, Claudette Oldenburg, Hester Rutgers, Emiel Schröder, Carolien Sonke, Gabe Vijver, Koen van de Wesseling, Jelle Description Breast pathologist and research physician focusing on the role of the DCIS microenvironment in progression to invasive breast cancer. Breast radiation oncologist and senior principal investigator (PI) with a long-standing track record in optimizing radiotherapy in breast-conserving treatment of breast cancer. Radiation oncologist in training; her PhD research focused on prevention over overtreatment of the axilla in breast cancer. Breast pathologist and research physician, focusing on developing a clinical risk prediction tool useful to predict which DCIS lesion is likely to become hazardous and which one not. Considered as one of the most experienced consultant breast pathologist worldwide. His skills to put histopathological diagnostic findings into a clinical relevant context are well recognized. Pathologist analyzing the molecular make-up of breast lesions and translating this into clinically useful information determining subsequent breast lesion management. Breast medical oncologist and senior PI focusing on finding biomarkers predictive of treatment efficacy. Molecular biologist, focusing on developing and validating tests predicting response to neoadjuvant breast cancer treatment. Breast radiologist, conducting PhD research on evaluating and improving monitoring response to neoadjuvant breast cancer treatment by imaging. Breast surgeon with a focus on breast-conserving treatment and impact of breast cancer on the quality of life and performance of breast cancer patients. Breast surgeon and senior PI with a long-standing track record in how we could do less in the treatment of breast cancer and potential precursor lesions without compromising outcome. Medical oncologist and senior PI, focusing on individualized breast cancer treatment, based on molecular characteristics in translational clinical trials, covering the entire spectrum from early- to large nationwide studies. Medical oncologist, epidemiologist, and PI, focusing on optimizing treatment of HER2-postive and oligometastatic breast cancer. Consultant breast pathologist and cytopathologist, focusing on immunotherapy, immune responses and tumor infiltrating lymphocytes in breast cancer. Consultant breast pathologist and senior PI, focusing on distinguishing harmless from hazardous DCIS biomarkers predicting response to systemic treatment.

6 Venue Antoni van Leeuwenhoek Hospital Conference Room Z4 Plesmanlaan CX Amsterdam, The Netherlands Language The official language of the course is English. Further information Christine Arkes, secretary Department of Pathology Antoni van Leeuwenhoek Hospital P.O. Box BE Amsterdam, The Netherlands Tel: / Fax: info@dutchbreastpathology.nl Registration online Registration deadline The deadline for registration is April 1, We can accommodate 50 participants. Fees Pathologists: 500,- Pathology residents: 300,- The fee includes internet access, material, lunch, coffee and tea during break as well as dinner on Wednesday May 18, Payments Your registration will only be valid after receiving your online payment of the registration fee. Cancellation policy For registration fees to be refunded, written notice of cancellation must be received by April 1, The amount of registration fees remitted, minus a 15 % handling fee, will be refunded after the course. Substitutions are accepted with written notification. After April 1, 2016, no refunds will be made. Hotels Dutch Design Hotel Artemis Room Reservation Form 17-mei-2016-reservation-form.pdf Accreditation All participants will receive a certificate as evidence of their attendance. The Dutch Society for Pathology has granted 14 CME points.

Name:... Department:... Hospital:... Address:... Telephone:... Fax:

Name:... Department:... Hospital:... Address:... Telephone:... Fax: 8th International Netherlands Cancer Institute Head and Neck Symposium Diagnosis and Treatment of Head and Neck Cancer: Controversies in Multidisciplinary Management Amsterdam, the Netherlands, November